Published by AimwellBio. Held by the cohort. Open to the field.
Every other intelligence tool publishes claims. AimwellBio publishes the Standard. The Founding Cohort holds it. The first 100 Signal and Shield subscribers receive it. The field cites it.
In 2026, biopharma decisions are increasingly informed by AI-generated intelligence — regulatory briefs, competitive landscapes, clinical signal summaries. The category has no operating standard. There is no common reference for what source-traced means, what counts as an adversarial verdict, how confidence scores should be constructed, when human review is non-negotiable.
The Adversarial Validation Standard, v1 is AimwellBio’s answer to that gap. It is not a marketing white paper. It is the operating reference the cohort holds the company to — published, versioned, and open to the field as the basis for every signal in the network.
How every output the network produces carries its source chain — from public registry to confidence-scored verdict.
Regulatory, Competitive, Trial Failure, Capital Risk — the four adversarial agents, what each interrogates, how they vote.
PROCEED / DELAY / KILL — the consensus logic, how dissent is preserved, when minority opinion overrides majority.
The math behind the score. How sources are weighted. How temporal decay affects confidence. When a score is too low to publish.
Where AI-generated content enters the chain. Where human review is non-negotiable. The containment boundary.
When the system gets it wrong — documented, with case examples, with corrections. The Standard does not pretend perfection.
How FHIN contributors are credentialed, how their signals are weighted, how the cohort polices itself.
The Founding Cohort Charter integrated. The terms AimwellBio operates under. The cohort’s right to revoke.
The Standard is a published document. Access is tiered — the Cohort and earliest subscribers hold it; the field reads the public abridged edition. Citation is open to anyone; the methodology reference is reserved for those whose work depends on it.
Cortellis, IQVIA, Citeline publish data products. AlphaSense publishes a search interface. None of them publish a Standard, because none of them are positioned to be held to one. AimwellBio is. The Cohort makes that claim enforceable. The Standard makes it citable. v1 is the first edition. v2 will be revised in public, with the Cohort’s input, with the field watching.
This is how a new category becomes the operating norm: someone publishes the reference, the reference gets cited, the citations become the field. AimwellBio is publishing first.
When you cite the methodology behind a decision, how defensible is the citation under cross-examination?
Plus: every Signal/Shield/Command subscriber gets the next published edition of The Standard, on release, before the field at large.
Hand us anything your team is about to use. We return a source-risk review with every citation traced. No sales call. No follow-up sequence. The review itself is the conversation.
The methodology that protects your work is also the methodology that protects your reputation when someone asks where the claim came from.
Cite The Standard In Your Next Brief →Teams searched documents, reviewed guidance updates, followed trial movement, tracked competitors, and built internal briefs by hand. Slow but auditable. Every claim had a paper trail.
Speed. The same brief that took a week now takes minutes. The trade-off: unsupported claims, stale guidance, missing context, and incomplete summaries can now move into serious decisions before anyone challenges them.
AimwellBio is the verification layer that sits between AI-generated intelligence and the decision someone signs their name to. Source-trace, adversarial review, confidence labels, institutional memory.
Seven ways unsupported scientific intelligence can enter regulatory, clinical, board, and investor workflows. Open to credentialed professionals. No sales sequence, no list-trading.